These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 2057440)

  • 21. Response to EPO therapy.
    Bommer J
    Przegl Lek; 1992; 49(1-2):36-7. PubMed ID: 1455003
    [No Abstract]   [Full Text] [Related]  

  • 22. Iron deficiency in patients with dialysis-associated anemia during erythropoietin replacement therapy: strategies for assessment and management.
    Van Wyck DB
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):21-4. PubMed ID: 2669082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients.
    Dunn CJ; Wagstaff AJ
    Drugs Aging; 1995 Aug; 7(2):131-56. PubMed ID: 7579784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing iron status in children with chronic renal failure on erythropoietin: which measurements should we use?
    Morris KP; Watson S; Reid MM; Hamilton PJ; Coulthard MG
    Pediatr Nephrol; 1994 Feb; 8(1):51-6. PubMed ID: 8142226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Individual differences in the efficacy of Recormon in patients with terminal kidney failure. The role of iron deficiency].
    Nikolaev AIu; Klepikov PV; Lashutin SV; Kondakhchan MA; Rogov VA; Trofimova EI
    Ter Arkh; 1993; 65(6):45-8. PubMed ID: 8378849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Who should receive recombinant human erythropoietin?
    Van Stone JC
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):3-7. PubMed ID: 2669084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The adverse effects of recombinant human erythropoietin therapy.
    Wong KC; Li PK; Lui SF; Nicholls MG; Lai KN
    Adverse Drug React Acute Poisoning Rev; 1990; 9(4):183-206. PubMed ID: 2088088
    [No Abstract]   [Full Text] [Related]  

  • 28. Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis.
    Faulds D; Sorkin EM
    Drugs; 1989 Dec; 38(6):863-99. PubMed ID: 2693045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
    Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
    Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anemia and erythropoietin in hemodialysis and continuous ambulatory peritoneal dialysis.
    Korbet SM
    Kidney Int Suppl; 1993 Feb; 40():S111-9. PubMed ID: 8445832
    [No Abstract]   [Full Text] [Related]  

  • 31. Historical review on the use of recombinant human erythropoietin in chronic renal failure.
    Winearls CG
    Nephrol Dial Transplant; 1995; 10 Suppl 2():3-9. PubMed ID: 7644103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of the treatment with human recombinant erythropoietin on anemia in children with end-stage kidney failure. French multicenter study].
    Sinnassamy P; Andre JL; Treize G; Leroy B
    Arch Fr Pediatr; 1993 Mar; 50(3):201-8. PubMed ID: 8338412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure.
    Dunn CJ; Markham A
    Drugs; 1996 Feb; 51(2):299-318. PubMed ID: 8808169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Administration of the same dose of epoetin-beta intravenously and subcutaneously to patients with renal anaemia.
    Steffensen GK; Stergaard O
    Scand J Urol Nephrol; 2011 Dec; 45(6):461-9. PubMed ID: 21736448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Initial response to treatment with erythropoietin in anemia caused by chronic renal insufficiency].
    Sánchez Casajús A; Barrau J; Gómez Alamillo C; Jaurrieta F
    Sangre (Barc); 1990 Feb; 35(1):82-4. PubMed ID: 2333585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of hemodialysis and peritoneal dialysis in the management of anemia related to chronic renal disease.
    Korbet SM
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):9-15. PubMed ID: 2648520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subcutaneous erythropoietin in the treatment of renal anaemia.
    Drinovec J; Varl J
    Przegl Lek; 1992; 49(1-2):38-40. PubMed ID: 1455004
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients.
    Mohini R
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):16-21. PubMed ID: 2648516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current and potential applications for erythropoietin.
    Pedrazzini A
    Acta Haematol; 1992; 87 Suppl 1():2-3. PubMed ID: 1574962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monitoring considerations in recombinant human erythropoietin therapy.
    Ogden DA
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):12-5. PubMed ID: 2669080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.